InvestmentAug 4, 2026, 07:07 AM
Camp4 Therapeutics Closes $50.1M Second Tranche Private Placement
AI Summary
Camp4 Therapeutics Corporation announced the closing of the second tranche of its previously announced private placement, securing approximately $50.1 million in gross proceeds. The capital will be utilized to advance CMP-002, a therapeutic candidate for SYNGAP1-related disorder, into a Phase 1/2 clinical trial, and to support the company's early-stage pipeline. The placement included common stock and pre-funded warrants, with participation from institutional investors such as Coastlands Capital and Janus Henderson Investors.
Key Highlights
- Closed second tranche of private placement, raising approximately $50.1 million.
- Issued 10,756,498 shares of common stock at $1.53 per share.
- Issued 21,925,368 pre-funded warrants at $1.5299 each.
- Proceeds to support advancement of CMP-002 into Phase 1/2 clinical trial.
- Funds also allocated for continued development of early-stage pipeline.
- Investors included Coastlands Capital, Janus Henderson Investors, and Vivo Capital.
Price Impact
More from CAMP